Terminated PHASE3 INTERVENTIONAL 2-arm NCT02422940

Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine. (MILESTONE℠)

An Extension Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine Extended-Release Tablets. for the Treatment of Chronic Post-Ischemic Stroke Walking Deficits .

Sponsor: Acorda Therapeutics

Conditions Post-ischemic Stroke

Interventions dalfampridine-ER 10 mg dalfampridine-ER 7.5 mg

Updated 11 times since 2017 Last updated: Jan 17, 2019 Started: Apr 30, 2015 Primary completion: Jan 31, 2017 Completion: Jan 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from Acorda Therapeutics

See all terminations from Acorda Therapeutics

Listed as NCT02422940, this PHASE3 trial focuses on Post-ischemic Stroke and remains terminated or withdrawn. Sponsored by Acorda Therapeutics, it has been updated 11 times since 2015, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

11 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Jan 2023 — Jul 2024 [monthly]

Terminated PHASE3
Dec 2022 — Jan 2023 [monthly]

Terminated PHASE3

▶ Show 6 earlier versions

Jan 2021 — Dec 2022 [monthly]

Terminated PHASE3
Feb 2019 — Jan 2021 [monthly]

Terminated PHASE3
Sep 2018 — Feb 2019 [monthly]

Terminated PHASE3
Jun 2018 — Sep 2018 [monthly]

Terminated PHASE3
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE3

Status: Active Not Recruiting → Terminated
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE3

First recorded

Apr 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Acorda Therapeutics

Data source: Acorda Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlantis, United States , Avon, United States , Berkeley, United States , Boston, United States , Carlsbad, United States , Chapel Hill, United States , Chicago, United States , Colorado Springs, United States , Columbus, United States , Corvallis, United States and 51 more locations